1
|
Rábade-Castedo C, Zamarrón-Sanz C, Hermida-Ameijeiras Á, Abelleira-Paris R, Casal-Mouriño A, Ferreiro-Fernández L, Rodríguez-Núñez N, Ricoy-Gabaldón J, Toubes-Navarro ME, Álvarez-Dobaño JM, Valdés-Cuadrado L. Effect of an intensive tobacco cessation program on the smoker narrative: A content analysis and grounded theory. Tob Induc Dis 2024; 22:TID-22-40. [PMID: 38362270 PMCID: PMC10867740 DOI: 10.18332/tid/183607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Revised: 12/28/2023] [Accepted: 02/01/2024] [Indexed: 02/17/2024] Open
Abstract
INTRODUCTION The smoker's narrative during smoking quitting provides insight into aspects not fully explored in daily clinical practice. The aim of the study was to analyze the smoker narrative using two types of methodologies: content analysis and grounded theory, before and after smoking cessation intervention, provided to the smoker in a specialized Smoking Cessation Unit accredited by the Spanish Society of Pneumology and Thoracic Surgery. METHODS A prospective observational study of current smokers included in a tobacco cessation program between 2017 and 2020 was conducted at the Smoking Cessation Unit of Santiago de Compostela Health Area, Spain. Routine clinical variables and patient narrative data were collected. A descriptive analysis of the sample, the content of the textual corpus, and a grounded theory were performed in semi-structured interviews at baseline and at follow-up at 6 months. RESULTS A total of 116 patients were included (mean age 55.6 ± 10.6 years; 56.9% male; mean nicotine dependence score 5.7 ± 1.6). Quantitative analysis of the narrative shows that the most frequent phrases and words are associated with smoking, nicotine craving, and predisposition for smoking cessation. After the intervention, phrases related to the manifestation of abstinence, response to pharmacological treatment, and self-perception of smoking cessation were predominant. In the qualitative analysis, the most frequent categories in the smoker's textual corpus were dependence, motivation, and emotionality, which decreased after the intervention (11.4%, 21.4%, and 9.9%, respectively) accompanied by increased satisfaction (19.2%) and the manifestation of abstinence (21.5%). CONCLUSIONS Motivation, nicotine dependence, and sensitivity to emotions are all closely intertwined in the current smoker narrative and can be modified as a consequence of treatment.
Collapse
Affiliation(s)
- Carlos Rábade-Castedo
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, España
| | - Carlos Zamarrón-Sanz
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
| | - Álvaro Hermida-Ameijeiras
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, España
- Servicio de Medicina Interna, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
| | - Romina Abelleira-Paris
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
| | - Ana Casal-Mouriño
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
| | - Lucia Ferreiro-Fernández
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, España
| | - Nuria Rodríguez-Núñez
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
| | - Jorge Ricoy-Gabaldón
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
| | - María Elena Toubes-Navarro
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
| | - José Manuel Álvarez-Dobaño
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, España
| | - Luis Valdés-Cuadrado
- Servicio de Neumología, Complejo Hospitalario Universitario de Santiago de Compostela, Universitario de Santiago de Compostela, Santiago de Compostela, España
- Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, España
| |
Collapse
|
2
|
Toubes-Navarro ME, Gude-Sampedro F, Álvarez-Dobaño JM, Reyes-Santias F, Rábade-Castedo C, Rodríguez-García C, Lado-Baleato Ó, Lago-Fidalgo R, Sánchez-Martínez N, Ricoy-Gabaldón J, Casal-Mouriño A, Abelleira-Paris R, Riveiro-Blanco V, Zamarrón-Sanz C, Rodríguez-Núñez N, Lama-López A, Ferreiro-Fernández L, Valdés-Cuadrado L. A pulmonary rehabilitation program reduces hospitalizations in chronic obstructive pulmonary disease patients: A cost-effectiveness study. Ann Thorac Med 2023; 18:190-198. [PMID: 38058789 PMCID: PMC10697305 DOI: 10.4103/atm.atm_70_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2023] [Revised: 07/06/2023] [Accepted: 08/23/2023] [Indexed: 12/08/2023] Open
Abstract
BACKGROUND Although pulmonary rehabilitation (PR) is recommended in patients with chronic obstructive pulmonary disease (COPD), there is a scarcity of data demonstrating the cost-effectiveness and effectiveness of PR in reducing exacerbations. METHODS A quasi-experimental study in 200 patients with COPD was conducted to determine the number of exacerbations 1 year before and after their participation in a PR program. Quality of life was measured using the COPD assessment test and EuroQol-5D. The costs of the program and exacerbations were assessed the year before and after participation in the PR program. The incremental cost-effectiveness ratio (ICER) was estimated in terms of quality-adjusted life years (QALYs). RESULTS The number of admissions, length of hospital stay, and admissions to the emergency department decreased after participation in the PR program by 48.2%, 46.6%, and 42.5%, respectively (P < 0.001 for all). Results on quality of life tests improved significantly (P < 0.001 for the two tests). The cost of PR per patient and the cost of pre-PR and post-PR exacerbations were €1867.7 and €7895.2 and €4201.9, respectively. The PR resulted in a cost saving of €1826 (total, €365,200) per patient/year, and the gain in QALYs was+0.107. ICER was -€17,056. The total cost was <€20,000/QALY in 78% of patients. CONCLUSIONS PR contributes to reducing the number of exacerbations in patients with COPD, thereby slowing clinical deterioration. In addition, it is cost-effective in terms of QALYs.
Collapse
Affiliation(s)
| | - Francisco Gude-Sampedro
- Department of Clinical Epidemiology, University Clinical Hospital of Santiago de Compostela, Spain
| | - José Manuel Álvarez-Dobaño
- Interdisciplinary Group of research in Pulmonology, Institute of Sanitary research from Compostela, Spain
- University Clinical Hospital of Santiago de Compostela, Spain
| | - Francisco Reyes-Santias
- Department of Human Resources and General Services, University Clinical Hospital of Santiago de Compostela, Spain
| | - Carlos Rábade-Castedo
- Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Spain
| | | | - Óscar Lado-Baleato
- Research Methods Group, Health Research Institute of Santiago de Compostela, Spain
- ISCIII Support Platforms for Clinical Research, Health Research Institute of Santiago de Compostela, Spain
| | - Raquel Lago-Fidalgo
- Department of Clinical Epidemiology, University Clinical Hospital of Santiago de Compostela, Spain
- Mathematics University of Santiago de Compostela, Spain
| | - Noelia Sánchez-Martínez
- Department of Clinical Epidemiology, University Clinical Hospital of Santiago de Compostela, Spain
- Mathematics University of Santiago de Compostela, Spain
| | - Jorge Ricoy-Gabaldón
- Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Spain
| | - Ana Casal-Mouriño
- Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Spain
| | - Romina Abelleira-Paris
- Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Spain
| | - Vanessa Riveiro-Blanco
- Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Spain
| | - Carlos Zamarrón-Sanz
- Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Spain
| | - Nuria Rodríguez-Núñez
- Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Spain
| | - Adriana Lama-López
- Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Spain
| | - Lucía Ferreiro-Fernández
- Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Spain
- Interdisciplinary Group of research in Pulmonology, Institute of Sanitary research from Compostela, Spain
| | - Luis Valdés-Cuadrado
- Department of Pulmonology, University Clinical Hospital of Santiago de Compostela, Spain
- Interdisciplinary Group of research in Pulmonology, Institute of Sanitary research from Compostela, Spain
- Medicine University of Santiago de Compostela, Spain
| |
Collapse
|
3
|
Casal-Mouriño A, Álvarez-Dobaño JM, Domínguez MJ, Gude F, Toubes ME, Lado-Baleato Ó, Martínez de Alegría A, Taboada M, Riveiro V, Rodríguez-Núñez N, Lama A, Ferreiro L, Otero B, Suárez-Antelo J, Pose A, Valdés L. Development of prognostic models to estimate the probability of lung injury one year after COVID-19-related hospitalization-a prospective study. J Thorac Dis 2023; 15:2971-2983. [PMID: 37426134 PMCID: PMC10323564 DOI: 10.21037/jtd-22-1565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Accepted: 03/24/2023] [Indexed: 07/11/2023]
Abstract
Background Long-term effects of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection still under study. The objectives of this study were to identify persistent pulmonary lesions 1 year after coronavirus disease 2019 (COVID-19) hospitalization and assess whether it is possible to estimate the probability that a patient develops these complications in the future. Methods A prospective study of ≥18 years old patients hospitalized for SARS-COV-2 infection who develop persistent respiratory symptoms, lung function abnormalities or have radiological findings 6-8 weeks after hospital discharge. Logistic regression models were used to identify prognostic factors associated with a higher risk of developing respiratory problems. Models performance was assessed in terms of calibration and discrimination. Results A total of 233 patients [median age 66 years [interquartile range (IQR): 56, 74]; 138 (59.2%) male] were categorized into two groups based on whether they stayed in the critical care unit (79 cases) or not (154). At the end of follow-up, 179 patients (76.8%) developed persistent respiratory symptoms, and 22 patients (9.4%) showed radiological fibrotic lesions with pulmonary function abnormalities (post-COVID-19 fibrotic pulmonary lesions). Our prognostic models created to predict persistent respiratory symptoms [post-COVID-19 functional status at initial visit (the higher the score, the higher the risk), and history of bronchial asthma] and post-COVID-19 fibrotic pulmonary lesions [female; FVC% (the higher the FVC%, the lower the probability); and critical care unit stay] one year after infection showed good (AUC 0.857; 95% CI: 0.799-0.915) and excellent performance (AUC 0.901; 95% CI: 0.837-0.964), respectively. Conclusions Constructed models show good performance in identifying patients at risk of developing lung injury one year after COVID-19-related hospitalization.
Collapse
Affiliation(s)
- Ana Casal-Mouriño
- Pulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | | | - María Jesús Domínguez
- Internal Medicine Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - Francisco Gude
- Clinical Epidemiology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - María E. Toubes
- Pulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - Óscar Lado-Baleato
- Research Methods Group (RESMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
- ISCIII Support Platforms for Clinical Research, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | | | - Manuel Taboada
- Anesthesia and Resuscitation Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - Vanessa Riveiro
- Pulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - Nuria Rodríguez-Núñez
- Pulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - Adriana Lama
- Pulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - Lucía Ferreiro
- Pulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - Borja Otero
- Esteve Teijin Company, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - Juan Suárez-Antelo
- Pulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - Antonio Pose
- Internal Medicine Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
- Research Methods Group (RESMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
- Esteve Teijin Company, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
| | - Luis Valdés
- Pulmonology Department, Clinical University Hospital of Santiago, Santiago de Compostela, Spain
- Research Methods Group (RESMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
- Medicine Department, University of Santiago, Santiago de Compostela, Spain
| |
Collapse
|
4
|
Torres-Durán M, Casal-Mouriño A, Ruano-Ravina A, Provencio M, Parente-Lamelas I, Hernández-Hernández J, Vidal-García I, Varela-Lema L, Valdés Cuadrado L, Fernández-Villar A, Barros-Dios J, Pérez-Ríos M. Residential radon and lung cancer characteristics at diagnosis. Int J Radiat Biol 2021; 97:997-1002. [PMID: 33856283 DOI: 10.1080/09553002.2021.1913527] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
PURPOSE This study sought to ascertain whether there might be an association between radon concentrations and age, gender, histologic type, and tumor stage at diagnosis. MATERIALS AND METHODS Lung cancer cases from different multicenter case-control studies were analyzed, and clinical data were retrieved from electronic health records and personal interviews. A radon device was placed in all dwellings of participants, and we then tested the existence of an association between residential radon and lung cancer characteristics at diagnosis. RESULTS Of the total of 829 lung cancer cases included, 56.7% were smokers or ex-smokers. There was no association between indoor radon concentrations and age, gender, histologic type or tumor stage at diagnosis. Median indoor radon concentrations increased with age at diagnosis for men, but not for women. When analyzing participants exposed to more than 1000 Bq/m3, a predominance of small cell lung cancer and a higher presence of advanced stages (IIIB and IV) were observed. CONCLUSIONS There seems to be no association between radon and age, gender, histologic type or tumor stage at diagnosis. Higher radon exposure is more frequent in the case of small-cell lung cancer.
Collapse
Affiliation(s)
| | - Ana Casal-Mouriño
- Service of Neumology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
| | - Alberto Ruano-Ravina
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Instituto de Investigaciones Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Mariano Provencio
- Service of Medical Oncology, Puerta del Hierro University Hospital, Madrid, Spain
| | | | | | - Iria Vidal-García
- Service of Neumology, University Hospital of A Coruña, A Coruña, Spain
| | - Leonor Varela-Lema
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Instituto de Investigaciones Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Luis Valdés Cuadrado
- Service of Neumology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
| | | | - Juan Barros-Dios
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Instituto de Investigaciones Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Mónica Pérez-Ríos
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología y Salud Pública, CIBERESP), Madrid, Spain.,Instituto de Investigaciones Sanitarias de Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| |
Collapse
|
5
|
Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, Rodríguez-Martínez Á, Giraldo-Osorio A, Varela-Lema L, Pereiro-Brea T, Barros-Dios JM, Valdés-Cuadrado L, Pérez-Ríos M. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res 2021; 10:506-518. [PMID: 33569332 PMCID: PMC7867742 DOI: 10.21037/tlcr.2020.03.40] [Citation(s) in RCA: 40] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Stage III non-small cell lung cancer (NSCLC) includes a highly heterogeneous group of patients with differences in the extent and localization of disease. Many aspects of stage III disease are controversial. The data supporting treatment approaches are often subject to a number of limitations, due to the heterogeneous patient populations involved in the trials. Furthermore, the definition of stage III disease has changed over time, and early studies were frequently inadequately powered to detect small differences in therapeutic outcome, were not randomized, or had a limited follow-up times. Major improvements in therapy, including the use of more active chemotherapy agents and refinements in radiation and surgical techniques, also limit the interpretation of earlier clinical trials. Lastly, improvements in pretreatment staging have led to reclassification of patients with relatively minimal metastatic disease as stage IV rather than stage III, leading to an apparent increase in the overall survival of both stage III and IV patients. Median overall stage III NSCLC survival ranges from 9 to 34 months. Higher survival rates are observed in younger Caucasian women with good performance status, adenocarcinoma, mutations, stage IIIA, and in patients with multidisciplinary-team-based diagnoses.
Collapse
Affiliation(s)
- Ana Casal-Mouriño
- Department of Pneumology, Santiago de Compostela University Clinical Teaching Hospital, Galicia, Spain.,Department of Preventive Medicine and Public Health, University of Santiago de Compostela, A Coruña, Spain
| | - Alberto Ruano-Ravina
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, A Coruña, Spain.,Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública/CIBERESP), Madrid, Spain
| | - María Lorenzo-González
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, A Coruña, Spain.,Population Screening Unit, Galician Regional Health Authority, Santiago de Compostela, Spain
| | - Ángeles Rodríguez-Martínez
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, A Coruña, Spain.,Department of Oncology, Pontevedra University Hospital Complex, Pontevedra, Spain
| | - Alexandra Giraldo-Osorio
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, A Coruña, Spain.,Research Group for Health Promotion and Disease Prevention, Department of Public Health, University of Caldas, Manizales, Colombia
| | - Leonor Varela-Lema
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, A Coruña, Spain.,Scientific-Technical Advisory Unit, Galician Health Technology Assessment Agency, Health Knowledge Management Agency (Unidade de Asesoramento Científico-técnico/avalia-t, Axencia de Coñecemento en Saúde/ACIS), Galician Regional Health Authority, Galicia, Spain
| | - Tara Pereiro-Brea
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, A Coruña, Spain.,Department of Pneumology, A Coruña University Teaching Hospital Complex, A Coruña, Spain
| | - Juan Miguel Barros-Dios
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, A Coruña, Spain
| | - Luis Valdés-Cuadrado
- Department of Pneumology, Santiago de Compostela University Clinical Teaching Hospital, Galicia, Spain.,Interdisciplinary Group of Research in Pulmonology, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
| | - Mónica Pérez-Ríos
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, A Coruña, Spain.,Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública/CIBERESP), Madrid, Spain
| |
Collapse
|
6
|
Casal-Mouriño A, Ruano-Ravina A, Torres-Durán M, Parente-Lamelas I, Provencio-Pulla M, Castro-Añón O, Vidal-García I, Abal-Arca J, Piñeiro-Lamas M, Fernández-Villar A, Valdés-Cuadrado L, Barros-Dios JM, Pérez-Ríos M. Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer. Sci Rep 2020; 10:21147. [PMID: 33273562 PMCID: PMC7713126 DOI: 10.1038/s41598-020-78051-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Accepted: 11/11/2020] [Indexed: 01/05/2023] Open
Abstract
Polymorphisms in DNA repair pathways may play a relevant role in lung cancer survival in never-smokers. Furthermore, they could be implicated in the response to chemotherapy and toxicity of platinum agents. The aim of this study was to evaluate the influence of various genetic polymorphisms in the BER and NER DNA repair pathways on survival and toxicity in never-smoker LC patients. The study included never-smokers LC cases diagnosed from 2011 through 2019, belonging to the Lung Cancer Research In Never Smokers study. A total of 356 never-smokers cases participated (79% women; 83% adenocarcinoma and 65% stage IV). Survival at 3 and 5 years from diagnosis was not associated with genetic polymorphisms, except in the subgroup of patients who received radiotherapy or chemo-radiotherapy, and presented with ERCC1 rs3212986 polymorphism. There was greater toxicity in those presenting OGG1 rs1052133 (CG) and ERCC1 rs11615 polymorphisms among patients treated with radiotherapy or chemo-radiotherapy, respectively. In general, polymorphisms in the BER and NER pathways do not seem to play a relevant role in survival and response to treatment among never-smoker LC patients.
Collapse
Affiliation(s)
- Ana Casal-Mouriño
- Department of Pneumology, Santiago de Compostela University Clinical Teaching Hospital, Santiago de Compostela, Spain.,Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/San Francisco s/n, 15782, Santiago de Compostela, Spain
| | - Alberto Ruano-Ravina
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/San Francisco s/n, 15782, Santiago de Compostela, Spain. .,Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología and Salud Pública-CIBERESP), Madrid, Spain. .,C013 Group-Health Research Institute of Santiago de Compostela (Instituto Investigación Sanitaria de Santiago de Compostela/IDIS), Santiago de Compostela, Spain.
| | - María Torres-Durán
- Department of Pneumology, Vigo University Teaching Hospital Complex, Vigo, Spain
| | | | | | | | - Iria Vidal-García
- Department of Pneumology, A Coruña University Teaching Hospital Complex, Vigo, Spain
| | - José Abal-Arca
- Department of Pneumology, Ourense University Teaching Hospital Complex, Ourense, Spain
| | - María Piñeiro-Lamas
- Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología and Salud Pública-CIBERESP), Madrid, Spain
| | | | - Luis Valdés-Cuadrado
- Department of Pneumology, Santiago de Compostela University Clinical Teaching Hospital, Santiago de Compostela, Spain.,Interdisciplinary Neumology Research Group, Health Research Institute of Santiago de Compostela (Instituto Investigación Sanitaria de Santiago de Compostela/IDIS), Santiago de Compostela, Spain
| | - Juan Miguel Barros-Dios
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/San Francisco s/n, 15782, Santiago de Compostela, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología and Salud Pública-CIBERESP), Madrid, Spain
| | - Mónica Pérez-Ríos
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/San Francisco s/n, 15782, Santiago de Compostela, Spain.,Consortium for Biomedical Research in Epidemiology and Public Health (CIBER en Epidemiología and Salud Pública-CIBERESP), Madrid, Spain.,C013 Group-Health Research Institute of Santiago de Compostela (Instituto Investigación Sanitaria de Santiago de Compostela/IDIS), Santiago de Compostela, Spain
| |
Collapse
|
7
|
Casal-Mouriño A, Ruano-Ravina A, Torres-Durán M, Parente-Lamelas I, Provencio-Pulla M, Castro-Añón O, Vidal-García I, Pena-Álvarez C, Abal-Arca J, Piñeiro-Lamas M, Fuente-Merino I, Fernández-Villar A, Abdulkader I, Valdés-Cuadrado L, Barros-Dios JM, Pérez-Ríos M. Corrigendum to "Lung cancer survival in never-smokers and exposure to residential radon: Results of the LCRINS study" [Canc. Lett. 487 (2020) 21-26]. Cancer Lett 2020; 493:10. [PMID: 32810636 DOI: 10.1016/j.canlet.2020.07.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- Ana Casal-Mouriño
- Department of Pneumology, Santiago de Compostela University Clinical Teaching Hospital, Santiago de Compostela, Spain; Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Alberto Ruano-Ravina
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública - CIBERESP), Spain.
| | - María Torres-Durán
- Department of Pneumology, Vigo University Teaching Hospital Complex, Vigo, Spain
| | | | | | | | - Iria Vidal-García
- Department of Pneumology, A Coruña University Teaching Hospital Complex, Spain
| | | | - José Abal-Arca
- Department of Pneumology, Ourense University Teaching Hospital Complex, Ourense, Spain
| | - María Piñeiro-Lamas
- Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública - CIBERESP), Spain
| | - Ismael Fuente-Merino
- Environmental Radioactivity Laboratory (Laboratorio de Radiactividad Ambiental - LARUC), University of Cantabria, Spain
| | | | - Ihab Abdulkader
- Department of Pathology, Clinic University Hospital of Santiago de Compostela, Spain
| | - Luis Valdés-Cuadrado
- Department of Pneumology, Santiago de Compostela University Clinical Teaching Hospital, Santiago de Compostela, Spain; Interdisciplinary Neumology Research Group, Health Research Institute of Santiago de Compostela (Instituto Investigación Sanitaria de Santiago de Compostela/IDIS), Spain
| | - Juan Miguel Barros-Dios
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública - CIBERESP), Spain; Department of Preventive Medicine, Santiago de Compostela University Teaching Hospital Complex, Santiago de Compostela, Spain
| | - Mónica Pérez-Ríos
- Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública - CIBERESP), Spain
| |
Collapse
|